Fact-checked by Grok 2 weeks ago

Gynecomastia

Gynecomastia is the benign proliferation of glandular breast tissue in males, resulting from an imbalance in the ratio of estrogen to androgen activity that favors estrogen.^[1] This condition typically presents as enlarged, firm, or tender breast tissue beneath the nipple-areola complex and can affect one or both breasts unevenly.^[2] It is distinguished from pseudogynecomastia, which involves fat deposition without glandular proliferation.^[3] The condition is most prevalent during physiological stages of hormonal change, including neonatal life (affecting over 50% of newborns due to maternal estrogens, usually resolving within 2-3 weeks), puberty (up to 60% of boys by age 14, often self-limiting within 6 months to 2 years), and senescence (36-57% of men over 60 years).^[1]^[2] Pathologic gynecomastia arises from underlying medical conditions such as hypogonadism, hyperthyroidism, liver or kidney failure, or tumors (e.g., testicular, adrenal, or pituitary neoplasms) that disrupt hormone balance.^[3] Common iatrogenic causes include medications like anti-androgens, spironolactone, chemotherapy agents, and anabolic steroids, as well as recreational substances such as marijuana, heroin, and alcohol.^[2] Symptoms often include breast tenderness, pain, or sensitivity, particularly in the early stages, with nipple discharge or asymmetry in more persistent cases.^[1] Diagnosis involves a thorough history, physical examination to assess glandular tissue (typically ≥2 cm subareolar), and targeted laboratory tests such as serum testosterone, estradiol, luteinizing hormone (LH), and human chorionic gonadotropin (hCG) to identify underlying etiologies.^[3] Imaging like testicular ultrasound or mammography may be indicated if malignancy is suspected.^[2] Treatment focuses on addressing reversible causes, with many physiologic cases resolving spontaneously without intervention.^[1] For persistent or symptomatic gynecomastia, medical options like selective estrogen receptor modulators (e.g., tamoxifen) can reduce breast volume in recent-onset cases, though evidence is limited.^[3] Surgical interventions, including liposuction or glandular excision, are reserved for longstanding cases causing psychological distress or functional impairment.^[2] Complications are rare but may include emotional distress from body image concerns, particularly in adolescents.^[1]

Overview

Definition

Gynecomastia is defined as the benign proliferation of glandular breast tissue in males, characterized by an increase in ductal and stromal components of the breast.^[4] This condition results from a relative excess of estrogen activity or deficiency in androgen action, leading to the development of palpable breast enlargement.^[5] Unlike malignant breast conditions, gynecomastia is non-cancerous and typically self-limited in physiological cases.^[1] It is important to distinguish gynecomastia from pseudogynecomastia (also known as adipomastia), which involves enlargement of the male breast primarily due to accumulation of subcutaneous fat without proliferation of glandular tissue.^[6] In pseudogynecomastia, the breast appears enlarged owing to excess adipose tissue, often associated with obesity, whereas true gynecomastia features a firm, rubbery subareolar mass upon palpation.^[7] This differentiation is crucial for appropriate clinical management, as pseudogynecomastia may respond to weight loss rather than targeted therapies for glandular hyperplasia.^[8] The male breast anatomically consists of glandular tissue, adipose tissue, and stroma, with minimal functional development compared to the female breast.^[9] In gynecomastia, the hallmark is hyperplasia of the ductal epithelium and periductal stroma, often progressing through stages from florid proliferation to fibrous remodeling.^[10] Gynecomastia affects up to 65% of males at some point in life, with peak incidences occurring in neonates (due to maternal estrogen exposure), during puberty (in up to 60% of adolescent boys), and in older age (involutional changes).^[7]^[1]

Epidemiology

Gynecomastia is a common condition affecting males across the lifespan, with an estimated global prevalence of 32-65% in males at some point in their lives, often transiently due to physiological hormonal fluctuations.^[11] In autopsy studies, the prevalence of asymptomatic gynecomastia has been reported as approximately 40%, highlighting its frequent occurrence without clinical detection.^[12] Prevalence varies significantly by age group, reflecting physiological peaks in hormonal activity. In neonates, gynecomastia occurs in 60-90% of cases due to maternal estrogen exposure, typically resolving within weeks to months.^[4] Among adolescents, the condition affects 50-60%, peaking during Tanner stages 2-3 of puberty, with most cases resolving spontaneously within 1-2 years.^[4]^[13] In older men, prevalence rises to 36-57%, and up to 70% in those aged 50-69 years, primarily attributable to age-related androgen decline and increased estrogen activity.^[4]^[1] Several risk factors contribute to the development of gynecomastia beyond physiological causes. Obesity is a key modifiable risk factor, as excess adipose tissue promotes peripheral aromatization of androgens to estrogens.^[1] Liver disease impairs estrogen metabolism, elevating circulating levels and increasing susceptibility.^[1] Certain medications, accounting for over 50% of pathologic cases, include antiandrogens, spironolactone, and antiretrovirals.^[14] In specific populations, such as HIV-infected men on highly active antiretroviral therapy, the prevalence is notably higher, often linked to hypogonadism and drug effects.^[15] Geographic variations in reported prevalence may stem from differences in diagnostic awareness and healthcare access, with higher rates documented in developed countries where screening is more routine.^[1] Recent trends indicate a rise in surgical interventions for gynecomastia, with 23,831 procedures performed in the United States in 2023 and 26,430 in 2024 (an 11% increase), driven by increased body image awareness and minimally invasive techniques.^[16]^[17] Although gynecomastia rarely progresses to malignancy, with male breast cancer comprising less than 1% of cases, it is associated with significant psychological morbidity.^[18] Affected males often experience anxiety, psychosocial discomfort, and fear of cancer, particularly during adolescence.^[9]

Clinical Presentation

Signs and Symptoms

Gynecomastia manifests primarily through physical enlargement of the breast tissue in males, which can occur unilaterally or bilaterally. The enlargement typically presents as a palpable, firm, or rubbery subareolar nodule, often disk-like and measuring 1-5 cm in diameter, distinct from mere adipose deposition in pseudogynecomastia. Asymmetry between the breasts is observed in approximately 25% of cases.^[19] Subjective symptoms include breast tenderness or pain, known as mastodynia, which affects 30-50% of individuals, particularly during the early stages of development. Nipple discharge is rare and may be milky or bloody, warranting further evaluation to rule out other conditions. Systemic symptoms are generally absent unless an underlying disease is present.^[19] The condition's presentation varies by duration: acute gynecomastia, with onset less than 6 months, is often tender and reversible; subacute cases last 6-12 months with intermediate features; and chronic gynecomastia, persisting beyond 12 months, becomes fibrotic and nontender due to stromal proliferation.^[19]^[20] Associated features are uncommon but include galactorrhea in less than 5% of cases, typically linked to hormonal influences. Axillary lymphadenopathy may occur if related to a tumor, though this is not a primary feature. These manifestations are often graded by severity, such as in the Simon classification, to assess extent.^[19]

Classification

Gynecomastia is classified using several systems that assess its severity, histological evolution, and underlying causes to inform clinical management. The most widely adopted clinical grading system is the Simon classification, originally proposed in 1973 and subsequently modified, which evaluates the extent of glandular tissue enlargement and skin redundancy based on physical examination.^[3] This system divides gynecomastia into four grades: Grade I consists of minor enlargement manifesting as a small button of palpable tissue concentrated around the areola without skin excess; Grade IIa involves moderate periareolar enlargement without skin excess; Grade IIb features moderate periareolar enlargement with moderate skin excess; Grade III represents marked breast enlargement without excess skin; and Grade IV denotes marked enlargement accompanied by significant skin excess, often resembling ptosis.^[3]^[21] Histological classification based on duration further categorizes gynecomastia into stages reflecting its progression: the early proliferative phase occurs within the first 4 months, characterized by cellular proliferation, ductal hyperplasia, and edema; the florid phase spans 4 to 12 months, marked by prominent ductal and stromal hyperplasia; and the fibrous phase develops after 12 months, dominated by stromal fibrosis and collagen deposition, rendering the tissue less responsive to non-surgical interventions.^[3] Etiologically, gynecomastia is broadly distinguished as physiologic, arising from normal hormonal fluctuations such as during infancy, puberty, or senescence without underlying disease, or pathologic, resulting from identifiable conditions like endocrine disorders, medications, or tumors.^[3] It may present unilaterally, more commonly associated with pathologic causes, or bilaterally, typical of physiologic cases.^[3] These classification systems guide management decisions by predicting resolution potential and surgical needs; for instance, Grade I and II gynecomastia, especially if of short duration (<12 months), often resolves spontaneously, whereas Grades III and IV or fibrous-stage cases frequently require surgical intervention due to persistent deformity and reduced elasticity.^[3]

Etiology

Physiologic Causes

Physiologic gynecomastia arises from transient hormonal imbalances during normal developmental transitions, leading to benign breast tissue enlargement without underlying disease. This condition manifests in three primary phases—neonatal, pubertal, and senescent—characterized by elevated estrogen relative to androgen levels, which stimulates glandular proliferation in the male breast. In most cases, no intervention is required as the imbalance self-corrects with time.^[1] Neonatal gynecomastia results from transplacental transfer of maternal estrogens and progestogens to the fetus, combined with a postnatal surge in luteinizing hormone that enhances testicular aromatization of androgens to estrogens. It affects 60% to 90% of newborn males, often presenting as bilateral, firm discoid enlargement under the nipple within the first week of life, sometimes accompanied by milky discharge known as "witch's milk." The condition typically resolves spontaneously within 2 to 4 weeks as maternal hormones clear and the infant's hypothalamic-pituitary-gonadal axis matures.^[22]^[1] Pubertal gynecomastia stems from a temporary surge in estrogen production, primarily through increased testicular aromatization of androgens during the hormonal flux of puberty, creating a transient estrogen-androgen imbalance. It occurs in 50% to 60% of boys aged 10 to 16 years, with peak incidence at 13 to 14 years, manifesting as unilateral or bilateral tenderness and enlargement. Approximately 75% to 90% of cases resolve spontaneously within 6 to 24 months as androgen levels rise and stabilize post-puberty.^[23]^[22]^[13]^[1] Senescent gynecomastia, associated with andropause, arises from age-related decline in testosterone production—approximately 1% per year after age 40—coupled with increased adipose tissue leading to higher aromatase activity and peripheral conversion of androgens to estrogens. This affects 25% to 65% of men over 50 years, with prevalence rising to 36% to 57% in those over 60, often presenting as bilateral, nontender enlargement that may persist due to ongoing hormonal shifts.^[1]^[24]

Pathologic Causes

Pathologic gynecomastia arises from underlying medical conditions or external factors that disrupt the balance between estrogen and androgen activity, leading to glandular breast tissue proliferation in males beyond normal physiologic stages. These causes account for a significant portion of cases in adults, often requiring identification and management of the primary disorder to resolve or mitigate the gynecomastia. Common pathologic triggers include drug exposures, endocrine disorders like hypogonadism, systemic chronic diseases, neoplasms, and miscellaneous conditions such as obesity or nutritional shifts.^[1] Drug-induced gynecomastia represents 10-25% of all cases and typically manifests 1-6 months after initiation of the offending agent, through mechanisms such as direct estrogenic effects, androgen receptor blockade, or inhibition of testosterone synthesis.^[25] Notable examples include spironolactone, an androgen receptor blocker used in heart failure and hypertension, which causes gynecomastia in up to 10% of users; antiandrogens like finasteride for benign prostatic hyperplasia; exogenous estrogens; marijuana via phytoestrogenic compounds; anabolic steroids that suppress endogenous testosterone; and antiretrovirals such as efavirenz in HIV treatment.^[1] Discontinuation of the drug often leads to regression within months, though persistent cases may require intervention.^[3] Hypogonadism, characterized by deficient testosterone production relative to estrogen, is a key pathologic cause, resulting in unopposed estrogen action on breast tissue. Primary hypogonadism, such as Klinefelter syndrome (prevalence of 1 in 500-1,000 newborn males), features small testes, elevated gonadotropins, and low testosterone, with gynecomastia occurring in 50-80% of affected individuals.^[26]^[27] Secondary hypogonadism stems from pituitary or hypothalamic disorders, like tumors or Kallmann syndrome, similarly reducing testosterone and elevating the estrogen-to-androgen ratio.^[1] Chronic diseases contribute through altered hormone metabolism or binding proteins. In liver cirrhosis, impaired hepatic clearance of estrogens and increased sex hormone-binding globulin (SHBG) lead to gynecomastia in approximately 50% of patients.^[28] Renal failure, particularly in those on dialysis, is associated with a 40-50% prevalence due to Leydig cell dysfunction, elevated prolactin, and reduced testosterone clearance.^[9] Hyperthyroidism elevates SHBG and aromatase activity, increasing free estrogen levels and causing gynecomastia in 10-40% of cases.^[29] Tumors secreting estrogen, precursors, or human chorionic gonadotropin (hCG) account for 3-5% of pathologic gynecomastia but demand urgent evaluation due to malignancy risk. Testicular tumors, including Leydig cell (1-3% of testicular neoplasms) and Sertoli cell types, produce estrogen directly or via hCG stimulation, with about 20% of hCG-secreting variants leading to gynecomastia; up to 5-11% of men with testicular cancer present with this symptom.^[1]^[30] Adrenal tumors, often malignant, secrete estrogens or androgens that aromatize to estrogens. Ectopic hCG production from germ cell tumors (e.g., mediastinal) mimics gonadotropin excess.^[3] Other pathologic factors include refeeding syndrome following starvation, where rapid adipose mobilization elevates circulating estrogens, typically regressing within months.^[1] Obesity promotes peripheral aromatization of androgens to estrogens in adipose tissue, exacerbating the condition in overweight males.^[3] Idiopathic gynecomastia, lacking an identifiable cause, comprises about 25% of adult cases and is diagnosed after excluding other etiologies.^[3] Recent studies (2020-2025) indicate a rising association with COVID-19, including a 51.4% radiological prevalence in affected young men and endocrine disruptions in long COVID leading to hypogonadism, as well as gynecomastia from treatments like posaconazole for COVID-related infections.^[31]^[32]^[33]

Pathophysiology

Hormonal Imbalance Mechanisms

Gynecomastia arises primarily from an imbalance in the estrogen-to-androgen ratio at the breast tissue level, leading to stimulation of glandular proliferation. This endocrine disruption occurs through increased estrogen action relative to androgens, which normally inhibit ductal and stromal growth in males. The mechanisms involve both absolute changes in hormone levels and alterations in their bioavailability or receptor responsiveness, often triggered by physiological, pathologic, or iatrogenic factors.^[1] Estrogen excess plays a central role, where elevated estradiol levels stimulate periductal stromal expansion and epithelial proliferation in breast tissue. This can result from increased production, such as direct secretion by testicular tumors like Leydig or Sertoli cell neoplasms, or enhanced peripheral aromatization of androgens to estrogens in adipose tissue or liver, particularly in obesity or aging. Serum estradiol concentrations exceeding the normal male range of 10-40 pg/mL promote this ductal growth, as estrogens bind to receptors in mammary glands to upregulate proliferation pathways. Additionally, heightened estrogen receptor sensitivity can amplify effects even at normal levels.^[1]^[34] Androgen deficiency contributes by failing to counter estrogenic effects, as testosterone and its metabolite dihydrotestosterone normally suppress breast tissue development. Reduced testosterone levels below 300 ng/dL, as seen in primary hypogonadism (e.g., Klinefelter syndrome) or secondary causes, diminish this opposition, allowing estrogen dominance. The resultant estrogen-to-androgen ratio surpassing physiological thresholds—typically when free estrogen exceeds free androgen activity—drives glandular hyperplasia. This imbalance is evident in conditions where testosterone production is impaired, shifting the hormonal milieu toward feminization.^[1]^[35] Sex hormone-binding globulin (SHBG) modulates this imbalance by preferentially binding testosterone over estradiol, thereby reducing the pool of free, bioactive testosterone. Elevated SHBG levels, as occur in liver disease or aging, decrease free testosterone availability while leaving relatively more free estradiol, exacerbating the estrogen-androgen disparity. This binding dynamic effectively lowers androgenic opposition to estrogen-driven proliferation.^[1]^[36] Androgen resistance further disrupts the balance despite normal or elevated testosterone levels, as ineffective receptor signaling fails to inhibit estrogen effects. Genetic forms, such as partial androgen insensitivity syndrome due to mutations in the androgen receptor gene, or acquired resistance from drugs like antiandrogens, impair testosterone's anti-proliferative actions in breast tissue. In these cases, the hormonal milieu mimics relative androgen deficiency, promoting gynecomastia.^[1] Dysregulation of the hypothalamic-pituitary-gonadal (HPG) axis perpetuates these imbalances through disrupted feedback loops. Excess estrogen suppresses gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH) secretion, reducing testicular testosterone production and amplifying estrogen dominance. Human chorionic gonadotropin (hCG) from germ cell tumors can mimic LH, stimulating Leydig cells to overproduce both testosterone and estradiol, with subsequent aromatization favoring estrogen excess. These axis perturbations create a self-reinforcing cycle of hormonal disproportion leading to persistent glandular growth.^[1]

Non-Hormonal Mechanisms

In gynecomastia, proliferation pathways in breast tissue involve activation of estrogen receptor alpha (ERα), which triggers downstream signaling through insulin-like growth factor-1 (IGF-1) and epidermal growth factor (EGF). These pathways promote ductal hyperplasia and periductal edema, leading to glandular expansion independent of systemic hormone fluctuations once initiated.^[37]^[38] Chronic gynecomastia evolves through fibrotic changes, where transforming growth factor-beta (TGF-β) is upregulated, driving collagen deposition and stromal fibrosis. This process replaces proliferative glandular elements with dense, less responsive connective tissue, contributing to the irreversible nature of long-standing cases.^[1]^[3] Genetic factors play a key role in certain forms of gynecomastia, including X-linked conditions such as partial androgen insensitivity syndrome caused by mutations in the androgen receptor (AR) gene. These mutations impair AR function, leading to unopposed breast tissue growth. Chromosomal abnormalities, notably Klinefelter syndrome (47,XXY karyotype), arise from an extra X chromosome, which alters gene dosage and promotes mammary proliferation through mechanisms tied to the supernumerary X.^[39]^[40]^[41] Paracrine effects within breast tissue further sustain gynecomastia via local growth factors, including IGF-1 and EGF secreted by stromal and ductal cells, which stimulate glandular cell survival and expansion. These factors confer resistance to apoptosis in glandular cells, preventing programmed cell death and maintaining tissue hyperplasia even after initial triggers subside.^[38]

Diagnosis

History and Physical Examination

The initial evaluation of suspected gynecomastia begins with a detailed history to identify potential etiologies and guide further assessment. Key elements include the onset and duration of breast enlargement, as acute development (within weeks to months) often indicates a reversible cause, while chronic cases exceeding 12 months suggest fibrosis.^[1] Patients should be queried about associated pain or tenderness, which is common in early proliferative phases but less so in established disease.^[3] A thorough medication review is essential, focusing on recent initiations of agents such as spironolactone, antiandrogens, estrogens, or substances like marijuana and anabolic steroids, which can precipitate glandular proliferation.^[1] Family history should probe for hereditary conditions like Klinefelter syndrome or genetic hypogonadism, while systemic symptoms—such as fatigue, jaundice, or weight loss—may signal underlying liver disease, hyperthyroidism, or renal failure.^[3] Physical examination follows, emphasizing a systematic approach to confirm gynecomastia and exclude mimics. Breast palpation, performed with the patient supine and arms at sides, involves compressing tissue against the pectoral muscle to assess for a firm, rubbery subareolar disk of glandular tissue, typically mobile and symmetric if bilateral.^[42] Size measurement using calipers across the glandular mass is recommended; a diameter greater than 2 cm supports the diagnosis of true gynecomastia, distinguishing it from pseudogynecomastia due to adipose tissue alone.^[1] The exam should evaluate for asymmetry, skin changes, nipple discharge, or axillary lymphadenopathy, alongside a complete genital assessment including testicular palpation for masses or atrophy and, in adolescents, Tanner staging to contextualize pubertal development.^[3] Certain findings raise concern for alternative pathologies, including rapid onset, unilateral involvement, a hard or fixed mass, or eccentric location away from the nipple-areolar complex, which, although the risk of malignancy is low (less than 1% in most series of gynecomastia patients), necessitate prompt biopsy to rule out breast cancer.^[1]

Differential Diagnosis

The differential diagnosis for gynecomastia encompasses several conditions that can present with male breast enlargement, requiring careful clinical distinction to exclude non-benign etiologies.^[1] Pseudogynecomastia involves pure adipose tissue deposition, commonly seen in obesity, without glandular proliferation; it features soft, diffuse enlargement lacking a firm subareolar component, often confirmed by the absence of tenderness or nodularity on examination.^[43] Male breast cancer is a rare mimic, accounting for less than 1% of all breast cancer cases and presenting as a firm, eccentric, unilateral mass, potentially with nipple retraction, discharge, or axillary lymphadenopathy; risk factors include prior chest radiation exposure and BRCA2 mutations.^[43]^[44] Other benign and malignant conditions include abscess, which manifests as a painful, erythematous, unilateral swelling; lipoma, a soft, mobile subcutaneous mass without glandular involvement; and metastatic disease, such as from prostate cancer, appearing as a firm mass with possible systemic symptoms.^[1]^[43] Endocrine disorders can mimic gynecomastia through hormonal perturbations leading to breast tissue changes, such as hyperprolactinemia from pituitary adenoma, which suppresses gonadotropins and elevates estrogen activity, or hypothyroidism associated with myxedema and altered thyroid hormone levels affecting sex steroid balance.^[1] In evaluation, atypical features on physical examination—such as asymmetry, fixation, or skin changes—prompt consideration of biopsy to rule out malignancy, with the overall risk of breast cancer in gynecomastia patients estimated at less than 1%.^[3]^[43]

Laboratory and Imaging Studies

Laboratory and imaging studies play a crucial role in evaluating gynecomastia to identify underlying etiologies, rule out pathologic conditions such as tumors or endocrine disorders, and differentiate true glandular proliferation from pseudogynecomastia. These investigations are typically reserved for cases where history and physical examination suggest non-physiologic causes, such as rapid onset, asymmetry, tenderness, or associated systemic symptoms.^[1] Laboratory evaluation begins with assessment of sex hormones to detect imbalances in the estrogen-androgen axis. Key tests include measurement of total and free testosterone, estradiol (E2), luteinizing hormone (LH), follicle-stimulating hormone (FSH), human chorionic gonadotropin (hCG), prolactin, and sex hormone-binding globulin (SHBG). Additional panels encompass thyroid-stimulating hormone (TSH) to screen for hyperthyroidism, liver function tests to evaluate hepatic disease, and renal function tests for chronic kidney disease. Low free testosterone levels, such as below 50 pg/mL, or an elevated E2-to-testosterone ratio raise suspicion for hypogonadism or increased estrogen activity contributing to gynecomastia. Elevated hCG or prolactin may indicate testicular or pituitary tumors, respectively, while abnormal LH and FSH patterns help distinguish primary from secondary hypogonadism. According to the European Academy of Andrology (EAA) clinical practice guidelines, routine laboratory testing is recommended only when pathologic gynecomastia is suspected, as physiologic cases in adolescents or older men often show transient hormonal fluctuations without need for intervention.^[11]^[1]^[45] Imaging studies are employed selectively to confirm the nature of breast tissue and exclude malignancy. Breast ultrasound serves as the first-line modality, effectively distinguishing glandular gynecomastia (hypoechoic subareolar tissue with a radial pattern) from pseudogynecomastia (diffuse fatty infiltration) and assessing vascularity via Doppler to identify hypervascular lesions suggestive of neoplasm. Mammography is indicated for men over 50 years or in cases with suspicious features such as irregular masses, skin changes, or nipple discharge, offering a sensitivity of approximately 90% for detecting male breast cancer. Magnetic resonance imaging (MRI) is reserved for equivocal ultrasound or mammography findings, providing superior soft-tissue contrast to evaluate complex masses. Testicular ultrasound is warranted if hCG is elevated or testicular asymmetry/masses are noted on exam, to detect occult germ cell tumors that may secrete estrogen or hCG. The American College of Radiology (ACR) Appropriateness Criteria advise against routine imaging in men with clinical findings consistent with benign gynecomastia, emphasizing its use only for atypical presentations to avoid unnecessary radiation exposure.^[46]^[22]

Tissue Analysis

Tissue analysis through biopsy is indicated in cases of gynecomastia exhibiting atypical features, such as unilateral involvement, persistence beyond one year, or clinical suspicion of malignancy, including hard or irregular masses or nipple discharge.^[9]^[1]^[47] Several biopsy techniques are employed depending on the diagnostic needs. Fine-needle aspiration (FNA) provides cytological evaluation suitable for initial assessment, while core needle biopsy is preferred for evaluating tissue architecture and excluding malignancy, often guided by ultrasound.^[48]^[49]^[50] Excisional biopsy serves both diagnostic and therapeutic purposes, particularly in persistent or symptomatic cases requiring glandular removal.^[9] Histopathological examination reveals distinct phases of gynecomastia. The proliferative (florid) phase features ductal hyperplasia, periductal edema, increased stromal cellularity, and prominent vascularity.^[3]^[10] The fibrous phase, typically seen after one year, is characterized by dense collagen deposition, stromal fibrosis, and sparse, atrophic ducts with minimal cellular activity.^[3]^[10] Benign gynecomastia consistently lacks cellular atypia, nuclear pleomorphism, or mitotic activity that would suggest malignancy.^[48]^[51] Key immunohistochemical findings include estrogen receptor positivity in approximately 80-100% of cases, reflecting the hormonal drive of the condition, with progesterone receptor expression also common in ductal epithelium.^[52]^[53] Carcinoma in situ is rarely encountered in gynecomastia biopsies, occurring in fewer than 1% of evaluated cases, though vigilance is required in high-risk patients.^[54]^[55] Biopsy-related complications are uncommon but include hematoma in less than 5% of procedures and infection rates below 2%, with most resolving conservatively.^[47]^[56] As of 2024, research using single-cell RNA sequencing has identified CD13 as a differential gene expressed in both gynecomastia and male breast cancer tissues, potentially highlighting shared molecular features in their pathogenesis.^[57]

Management

Observation and Lifestyle Interventions

Observation and watchful waiting represent the primary non-invasive approach for managing mild or physiologic gynecomastia, particularly in neonatal and pubertal cases where no underlying pathology is identified.^[1] In neonates, gynecomastia often arises from maternal estrogen exposure and typically resolves spontaneously within 2 to 3 weeks without intervention.^[58] For pubertal gynecomastia, which affects up to 70% of adolescent males, approximately 90% of cases regress spontaneously within 1 to 3 years, emphasizing the importance of periodic monitoring rather than immediate action.^[58] Clinicians recommend reassessment every 3 to 6 months through physical examination to track regression or detect any progression suggestive of a pathologic cause.^[1] Lifestyle modifications play a supportive role in addressing gynecomastia, especially in cases associated with obesity or modifiable risk factors. Weight loss through caloric restriction and increased physical activity can reduce adipose tissue, thereby decreasing peripheral aromatization of androgens to estrogens and potentially diminishing breast prominence in obese individuals.^[59] A combination of aerobic exercise, such as running or swimming, and resistance training targeting the chest and core helps lower overall body fat percentage, improving chest contour without directly affecting glandular tissue.^[1] Additionally, avoiding known triggers like excessive alcohol consumption and marijuana use is advised, as these substances can disrupt hormonal balance by elevating prolactin or mimicking estrogen effects, exacerbating the condition.^[60] Compression garments offer a practical, non-invasive option for cosmetic relief during the observation period, providing temporary concealment of breast enlargement and psychological comfort. These form-fitting vests or shirts apply gentle pressure to flatten the chest area, making them suitable for daily wear in adolescents or adults awaiting natural resolution.^[61] Counseling forms an integral part of observation-based management, focusing on reassurance about the benign, self-limiting nature of physiologic gynecomastia to alleviate patient anxiety. Healthcare providers should educate patients on expected timelines for resolution, encourage adherence to lifestyle changes, and outline signs of progression—such as rapid enlargement, pain, or asymmetry—that warrant further evaluation.^[1] Regular follow-up ensures ongoing monitoring and adjustment of the care plan as needed.

Pharmacologic Treatment

Pharmacologic treatment for gynecomastia is primarily indicated for cases that are painful, of recent onset (typically less than 12 months), or associated with pathologic causes, as these are more likely to respond to medical intervention targeting hormonal imbalances. These treatments are off-label, supported by limited evidence from small clinical studies.^[62] It is generally not recommended for chronic fibrotic gynecomastia, where glandular tissue has become irreversible, or for physiologic cases that often resolve spontaneously.^[63] According to guidelines, initial steps include discontinuing any offending medications and addressing underlying conditions, with pharmacologic options reserved for symptomatic persistent gynecomastia.^[62] Selective estrogen receptor modulators (SERMs), such as tamoxifen and raloxifene, are considered first-line pharmacologic agents for symptomatic gynecomastia due to their ability to block estrogen effects in breast tissue. Tamoxifen, administered at 10-20 mg daily for 3-6 months, has demonstrated high efficacy, with studies reporting complete resolution in up to 90% of cases and at least 50% reduction in breast size in approximately 80% of pubertal patients within 3 months.^[64]^[65] Raloxifene, typically dosed at 60 mg daily, shows similar efficacy, achieving size reduction in 86-93% of patients, and may offer fewer side effects like hot flashes compared to tamoxifen, though evidence is more limited and tamoxifen remains more widely studied.^[66]^[18] Aromatase inhibitors, such as anastrozole at 1 mg daily, work by blocking the conversion of androgens to estrogens and are particularly useful in obesity-related or hypogonadism-associated gynecomastia. Clinical trials indicate size reductions of 36-72% in treated patients, with good responses observed as early as one month, though efficacy is less consistent in pubertal cases compared to SERMs.^[67]^[68] Androgen therapies, including testosterone replacement for confirmed hypogonadism, can address underlying deficiencies but carry risks of worsening gynecomastia if aromatization to estrogen is elevated. Danazol, a synthetic androgen dosed at 200-600 mg daily, has been used historically but shows limited efficacy (around 40% complete resolution) and is associated with virilization side effects, leading to its restricted use primarily in select pathologic cases.^[63]^[69] Pharmacologic approaches should be avoided in physiologic gynecomastia without symptoms.^[18] Common side effects of these treatments include hot flashes with SERMs; thromboembolism is rare with tamoxifen, particularly in short-term use. Aromatase inhibitors may cause joint pain or bone density loss with prolonged use. The Endocrine Society and other guidelines recommend SERMs as first-line for recent-onset symptomatic gynecomastia, with monitoring for response within 3-6 months.^[18]^[62] Tamoxifen remains the standard.

Surgical Treatment

Surgical treatment is indicated for gynecomastia that persists beyond two years, causes significant cosmetic distress, or is classified as Grade II-IV according to the Simon grading system, particularly after failure of medical therapy. Indications also include cases where the condition leads to psychological impairment or when the glandular tissue is fibrotic and unresponsive to non-operative measures. The primary surgical techniques involve liposuction to address the fatty component, often using ultrasound-assisted methods for improved precision and reduced trauma, and excision to remove glandular tissue, typically via a periareolar incision for milder cases or subcutaneous mastectomy for more severe involvement. Combined approaches, integrating liposuction and excision, are employed in approximately 70% of procedures to achieve optimal contouring and symmetry. For minimal scarring, endoscopic-assisted techniques may be utilized, while Grade IV cases with excess skin often require skin resection alongside glandular removal. Patient satisfaction rates following surgery exceed 90%, with high improvement in body image and quality of life reported in long-term follow-ups. Common complications include hematoma in about 5% of cases, asymmetry in up to 10%, and nipple-areola complex loss in less than 2%, though most are manageable with revision rates under 5%. Recent trends from 2023 to 2025 highlight a surge in minimally invasive options, such as laser-assisted lipolysis, which reduces recovery time and scarring compared to traditional methods. The global market for gynecomastia surgery is projected to grow to $1.8 billion by 2032, driven by increased awareness and reduced stigma around male cosmetic procedures. Contraindications for surgery include active infections, uncontrolled comorbidities such as bleeding disorders or heart disease, and ongoing hormonal therapies that may alter outcomes.

Prognosis

Clinical Outcomes

In pubertal gynecomastia, spontaneous resolution occurs in 75-90% of cases within 1 to 3 years, primarily due to the normalization of hormonal imbalances as puberty progresses.^[70] For adults with physiologic or idiopathic gynecomastia, spontaneous regression is uncommon, particularly in chronic cases, and often requires addressing underlying causes or intervention.^[1] Medical treatments, such as anti-estrogens like tamoxifen or clomiphene, achieve size reduction in 50-80% of early-stage cases, particularly when initiated within the first 12 months before significant fibrosis develops.^[63] Surgical interventions, including glandular excision and liposuction, generally yield high patient satisfaction rates (around 90%) and low recurrence rates (typically less than 10%), assuming complete glandular removal and management of underlying factors.^[71] The risk of malignancy associated with gynecomastia is less than 1%, and the condition itself does not confer an increased incidence of breast cancer beyond that attributable to predisposing factors like liver disease or endocrine disorders.^[72] For pathologic gynecomastia, prognosis improves significantly with treatment of the underlying cause, with resolution in most cases (over 80%) if addressed promptly before fibrosis develops.^[1] Follow-up involves annual clinical examinations to monitor for resolution or complications, with complete resolution defined by the absence of palpable glandular tissue on physical exam.^[1] In untreated chronic cases persisting beyond 12 months, progressive periductal fibrosis and stromal hyalinization lead to permanent structural changes in breast tissue, rendering spontaneous regression unlikely and often necessitating surgical correction for aesthetic and functional improvement.^[59] Gynecomastia often leads to significant body image distress among affected individuals, particularly adolescents, who may experience heightened self-consciousness about their physical appearance during a critical developmental stage. Studies indicate significantly elevated levels of anxiety, depression, and social phobia in adolescents with gynecomastia compared to the general population, with many meeting criteria for psychological diagnoses.^[73]^[74] This psychological burden frequently manifests in behavioral changes, such as avoidance of activities that expose the chest, including swimming, gym classes, or changing in locker rooms. Adolescents may wear loose clothing to conceal their breasts or withdraw from social interactions to evade scrutiny, further exacerbating feelings of isolation and low self-esteem. In severe untreated cases, the persistent distress has been associated with increased risk of suicidal ideation, underscoring the need for early intervention to mitigate long-term mental health risks.^[75]^[76] Socially, gynecomastia carries a strong stigma, often derogatorily referred to as "man boobs," which contributes to bullying and peer teasing, especially in school settings. Adolescents report higher rates of peer victimization, including verbal harassment and social exclusion, which intensify emotional distress and impair interpersonal relationships. The condition can also affect romantic relationships, as individuals may avoid intimacy due to embarrassment, leading to strained partnerships or delayed dating experiences. Professionally, gynecomastia may hinder career pursuits in fields emphasizing physical fitness, such as the military, where it can impact eligibility or performance standards during evaluations.^[77]^[75]^[78] To address these impacts, psychological interventions like counseling and participation in support groups play a vital role in helping individuals cope with body image issues and rebuild confidence. Counseling focuses on cognitive-behavioral strategies to challenge negative self-perceptions, while support groups provide a sense of community and shared experiences, reducing feelings of isolation. Following treatment, such as surgery, many report substantial improvements; for example, over 90% of patients express satisfaction with outcomes, noting enhanced self-esteem and overall quality of life.^[8]^[71] Recent studies highlight that gynecomastia affects 50-60% of adolescent males, a prevalence that normalizes the condition as a common pubertal variation, yet awareness campaigns continue to reduce associated shame by promoting open discussions and destigmatization efforts. Culturally, media portrayals have evolved, with celebrities like Dwayne Johnson and Simon Cowell publicly sharing their experiences with gynecomastia and post-surgical recovery, fostering greater acceptance and encouraging men to seek help without fear of judgment.^[79]^[80]^[81]

Historical and Cultural Context

Medical History

The recognition of gynecomastia dates back to ancient times, with early depictions appearing in Egyptian art from the 18th Dynasty (circa 1550–1292 BCE), where pharaohs such as Akhenaten and Tutankhamun were portrayed with feminine breast features suggestive of the condition, possibly reflecting familial or representational traits rather than pathological confirmation.^[82] Although medical papyri like the Edwin Smith Papyrus (circa 1600 BCE) describe swellings and tumors on the male breast, attributing them to vascular or inflammatory causes without specific terminology, the condition was more formally conceptualized in Greco-Roman medicine. In the 2nd century AD, the physician Galen coined the term "gynecomastia" from Greek roots meaning "woman's breast," describing it as an unnatural accumulation of fat in the male breast due to humoral imbalances, particularly excess phlegm or moisture leading to effeminacy.^[83] He differentiated it from true glandular proliferation, viewing it through the lens of the four humors, a framework that dominated medical thought for centuries.^[84] By the 19th century, gynecomastia gained attention through autopsy studies that documented its prevalence and pathology, revealing glandular hyperplasia in affected males rather than mere adiposity.^[85] The term was reintroduced and formalized in modern medical literature around 1834, building on Galen's etymology to describe noncancerous breast enlargement.^[86] A key association emerged with liver cirrhosis, as noted by Friedrich Theodor von Frerichs in 1861, who linked hepatic dysfunction to hormonal disruptions causing gynecomastia in his seminal work on liver diseases.^[87] This period saw initial surgical attempts, including excisions described by Paulus of Aegina in the 7th century but revived in European texts, though outcomes were limited by infection risks and poor understanding of etiology. The 20th century marked a shift toward hormonal etiology, with researchers in the 1930s establishing estrogen's role in stimulating breast tissue growth, particularly through experiments showing estrogen-androgen imbalances in affected males.^[88] Surgical techniques advanced in the mid-century; in 1946, John R. Webster introduced the semicircular intra-areolar incision for subcutaneous mastectomy, enabling glandular excision with minimal scarring, a method refined in the 1950s for better cosmetic results.^[89] Key milestones included the 1970s identification of drug-induced cases, such as spironolactone, where studies demonstrated its anti-androgenic effects leading to gynecomastia in up to 10% of users.^[90] In the 2000s, genetic insights deepened with research on Klinefelter syndrome (47,XXY), linking it to elevated estrogen levels and increased gynecomastia risk due to hypogonadism.^[91] Studies since the 2000s have emphasized environmental factors, with ongoing research as of 2025 highlighting endocrine disruptors like phthalates and essential oils (e.g., lavender and tea tree) as potential contributors to gynecomastia by mimicking estrogen or inhibiting androgens.^[92] Concurrently, advances in minimally invasive surgery, such as endoscopic-assisted liposuction and lipolysis, have improved outcomes for mild cases, reducing recovery time compared to traditional excision.^[93] These findings underscore ongoing research into multifactorial causes beyond classical hormonal imbalances.

Etymology and Societal Perceptions

The term gynecomastia originates from the Greek words gyne, meaning "woman," and mastos, meaning "breast," reflecting the condition's characteristic enlargement of male breast tissue resembling female physiology.^[3] It was first coined by the Greek physician Galen (130–200 AD), who described it as an abnormal proliferation of glandular tissue and fat in the male breast, often observed in eunuchs due to hormonal disruptions from castration.^[94] The word entered English usage in 1881, marking its formal adoption in medical literature to denote this benign yet hormonally driven enlargement.^[95] In Western societies, gynecomastia carries significant stigma, frequently perceived as a threat to traditional masculinity and leading to social devaluation or ridicule.^[96] Affected individuals often internalize shame, fearing feminization and marginalization, which can exacerbate psychological distress and body image issues aligned with hegemonic ideals of male muscularity.^[97] Ancient views, as noted by Galen, linked the condition to eunuchs, viewing it as a marker of emasculation rather than a natural variation, a perception that echoes in modern cultural taboos where enlarged male breasts challenge gender norms.^[86] Contemporary perceptions have evolved with greater visibility on social media platforms, where discussions and personal stories have surged since 2020, particularly during the COVID-19 pandemic, fostering awareness and reducing isolation for those affected.^[98] Celebrity disclosures, such as those by athletes like Dwayne Johnson, who has shared his experiences with the condition and subsequent surgery, have aided destigmatization by normalizing it as a treatable issue unrelated to personal failing.^[99] Globally, cultural attitudes vary; in India, for instance, gynecomastia is sometimes tied to traditional practices like neonatal breast expression—known as "witch's milk"—which can induce transient enlargement, though broader access to corrective surgery remains concentrated in urban centers due to economic and infrastructural disparities.^[100]^[101] These societal dynamics have influenced policy, particularly in the United States, where insurance coverage for gynecomastia surgery expanded in the 2010s for cases demonstrating medical necessity, such as persistent pain or severe emotional impairment, aligning with guidelines from professional societies to address both physical and psychosocial burdens.^[102]

References

[1]
Gynecomastia: Etiology, Diagnosis, and Treatment - Endotext - NCBI
Jan 6, 2023 · Gynecomastia is a relatively common disorder. Its causes range from benign physiological processes to rare neoplasms.ESTROGEN, GH AND IGF-1... · PHYSIOLOGIC... · PATHOLOGIC GYNECOMASTIA
[2]
Enlarged breasts in men (gynecomastia) - Symptoms and causes
Oct 26, 2023 · An imbalance of the hormones estrogen and testosterone causes it. Gynecomastia can affect one or both breasts, sometimes unevenly.
[3]
Gynecomastia - StatPearls - NCBI Bookshelf
Gynecomastia is an increase in male breast volume. This condition most often occurs during times of hormonal change such as at birth, during adolescence and in ...Gynecomastia · Pathophysiology · Treatment / Management
[4]
Gynecomastia: Pathophysiology, Evaluation, and Management - PMC
Gynecomastia, defined as benign proliferation of male breast glandular tissue, is usually caused by increased estrogen activity, decreased testosterone ...Clinical Manifestations And... · Diagnostic Approach · Cme Questions About...
[5]
Gynecomastia: pathophysiology, evaluation, and management
Gynecomastia, defined as benign proliferation of male breast glandular tissue, is usually caused by increased estrogen activity, decreased testosterone ...
[6]
A Unique Case of Unilateral Pseudogynecomastia - PMC - NIH
Sep 17, 2024 · Pseudogynecomastia, or lipomastia, on the other hand, involves the enlargement of the male breast due to the accumulation of subcutaneous fat ...<|separator|>
[7]
Gynecomastia - Conservative and Surgical Management - PubMed
Gynecomastia is defined as a unilateral or bilateral persistent benign mammary gland enlargement in men. Prevalence of asymptomatic gynecomastia is up to 65%.
[8]
Enlarged breasts in men (gynecomastia) - Diagnosis and treatment
Oct 26, 2023 · Gynecomastia often goes away over time without treatment. But if gynecomastia is caused by a medical condition, that condition may need treatment.Diagnosis · Conditions That Cause... · Treatment
[9]
Gynecomastia: Clinical evaluation and management - PMC
[5] Pseudogynecomastia and true gynecomastia can be differentiated by physical examination, as described above. Malign and benign conditions can be ...
[10]
Gynecomastia in Adolescent Males - PMC - NIH
Gynecomastia is defined as an enlargement of the male breast. It is often benign, and can be the source of significant embarrassment and psychological distress.Treatment · Fig. 2 · Abstract
[11]
EAA clinical practice guidelines—gynecomastia evaluation and ...
May 16, 2019 · Gynecomastia (GM) is a benign proliferation of the glandular tissue of the breast in men. It is a frequent condition with a reported prevalence of 32–65%.Missing: global | Show results with:global
[12]
[PDF] The Prevalence of Gynecomastia and Its Relationship With Age In ...
Jun 24, 2022 · On the other hand, the worldwide prevalence of GM has been reported between 32-65%, while autopsy data suggest a prevalence of 40% (14). The ...<|separator|>
[13]
Gynecomastia: Practice Essentials, Background, Etiology
Aug 1, 2024 · Pubertal gynecomastia usually has an onset in boys aged 10-12 years. It generally regresses within 18 months, and persistence is uncommon in men ...Missing: global | Show results with:global
[14]
Increased Morbidity in Males Diagnosed With Gynecomastia
Gynecomastia has 3 distinct age peaks during a life course: infancy, puberty, and older age. In infancy, an estimated 70% of newborn boys experience transient ...Missing: neonates | Show results with:neonates
[15]
The burden of gynecomastia among men on antiretroviral therapy in ...
The burden of gynecomastia among men on ART in Malawi was higher than previously reported, and was associated with adverse psychological consequences.
[16]
What's on the horizon? Plastic surgery trends for 2025 | ASPS
Jan 10, 2025 · ASPS statistics show a 5 percent increase in overall cosmetic surgery procedures between 2022 and 2023. There is no reason to believe that ...Missing: interventions | Show results with:interventions
[17]
Understanding Gynecomastia and Its Management - U.S. Pharmacist
Jun 14, 2024 · Male breast cancer is rare, as it constitutes approximately 0.2% of all male cancers. A breast examination is recommended in all male patients ...
[18]
Gynecomastia - Symptoms, diagnosis and treatment
Apr 15, 2025 · Gynecomastia is the proliferation of benign male glandular breast tissue. It may be unilateral or bilateral, painful, or asymptomatic.
[19]
https://bestpractice.bmj.com/topics/en-us/869
[20]
Classification and surgical correction of gynecomastia - PubMed
Classification and surgical correction of gynecomastia. Plast Reconstr Surg. 1973 Jan;51(1):48-52. doi: 10.1097/00006534-197301000-00009. Authors. B E Simon ...Missing: original paper
[21]
Gynecomastia | AAFP
Apr 1, 2012 · Gynecomastia is defined as benign proliferation of glandular breast tissue in men. Physiologic gynecomastia is common in newborns, adolescents, and older men.Abstract · Physiologic Gynecomastia · Nonphysiologic Gynecomastia · Diagnosis
[22]
Pubertal gynecomastia incidence among 530000 boys
Mar 6, 2024 · The prevalence varies widely (4%−69%). The incidence peaks are during neonatal, pubertal, and senescent periods. Its affect on emotional well- ...
[23]
Male menopause: Myth or reality? - Mayo Clinic
Mar 26, 2025 · Recognizing low testosterone levels. Men's testosterone levels generally fall about 1% a year after age 40. But most older men still have ...
[24]
Drug-induced gynecomastia - PubMed
Gynecomastia is caused by drugs in 10 - 25% of all cases. The pathophysiologic mechanism for some drugs includes exogenous estrogens exposure, ...Missing: prevalence | Show results with:prevalence
[25]
How many people are affected by or at risk for Klinefelter syndrome ...
Jan 3, 2025 · How many people are affected by or at risk for Klinefelter syndrome (KS)? Researchers estimate that 1 in about 500-1,000 newborn males has an ...
[26]
The Impact and Management of Gynaecomastia in Klinefelter ... - NIH
Gynecomastia is defined as a palpable enlargement of the male breast, secondary to an increase in the glandular and stromal breast tissue.
[27]
Study of Gonadal Hormones in Males With Liver Cirrhosis and ... - NIH
Jan 21, 2023 · mentions that 50% of patients with liver cirrhosis show signs of feminization, testicular atrophy, decreased libido, reduced secondary sex hair, ...
[28]
Unilateral gynecomastia as an initial presentation of hyperthyroid ...
Symptoms of bilateral gynecomastia in association with GD and thyrotoxicosis can be found in various reported clinical cases as frequently as 40% (1). However, ...Missing: prevalence | Show results with:prevalence
[29]
Nonseminomatous Testicular Tumors - StatPearls - NCBI Bookshelf
[46] However, male gynecomastia is found in about 5% of men with testicular cancer, presumably from elevated HCG levels.
[30]
COVID-19 and Gynecomastia: What is the Relationship? - PMC
May 11, 2020 · We found a high prevalence of radiological gynecomastia (51.4%) among COVID-19 younger (age 20 to 60 years) men which was greater than previous ...Missing: treatments | Show results with:treatments
[31]
Use of testosterone replacement therapy to treat long-COVID-related ...
Mar 22, 2024 · Here we report the first case of a patient affected with a long-COVID syndrome leading to hypogonadism and treated with testosterone replacement therapy (TRT)
[32]
Posaconazole-induced gynaecomastia in a patient with COVID-19 ...
Aug 6, 2025 · Posaconazole-induced gynaecomastia in a patient with COVID-19-associated mucormycosis: a case report.Missing: treatments | Show results with:treatments
[33]
Age-Specific Serum Total and Free Estradiol Concentrations in ... - NIH
The typical laboratory reference range for serum estradiol in men is 10 to 40 pg/mL [8]. However, serum estradiol ranges have not been established for optimal ...
[34]
What Is a Normal Testosterone Level for Young Men? Rethinking ...
Age-specific middle tertile levels were 409-558 ng/dL (20-24 years old), 413-575 ng/dL (25-29 years old), 359-498 ng/dL (30-34 years old), 352-478 ng/dL (35-39 ...
[35]
Laboratory Assessment of Testicular Function - Endotext - NCBI - NIH
Feb 29, 2020 · Free testosterone was calculated by the law-of-mass-action equation using of K SHBG-T of 0.998 × 109 L/mol and a K Alb-T of 3.57 × 104 L/mol.
[36]
Gynecomastia - MAMC Journal of Medical Sciences
Gynecomastia is a benign enlargement of the male breast tissue, either due to the proliferation of glandular tissue or deposition of fat in breast tissue.
[37]
Idiopathic gigantomastia: newer mechanistic insights implicating the ...
Sep 28, 2019 · However, there is a differential effect of various hormones, growth factors and cytokines in the normal breast, gynecomastia, gigantomastia and ...
[38]
Mammary Gland Development - PMC - PubMed Central
Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci ...
[39]
Androgen insensitivity syndrome: a review - PMC - PubMed Central
It results from alterations in the androgen receptor gene, leading to a frame of hormonal resistance, which may present clinically under 3 phenotypes: complete ...
[40]
Partial Androgen Insensitivity Syndrome Presenting with ...
Jun 30, 2015 · Androgen insensitivity syndrome (AIS) is a rare endocrine disorder presenting with gynecomastia and is a disorder of male sexual differentiation ...
[41]
Klinefelter Syndrome - StatPearls - NCBI Bookshelf
May 5, 2025 · The estimated prevalence is between 1 in 500 and 1 in 1000 males.[9] Diagnosis often occurs in adulthood, as many cases remain unidentified ...
[42]
Key stages in mammary gland development: The cues that regulate ...
Dec 5, 2005 · Thus it is driven by systemic hormonal stimuli that elicit local paracrine ... cells by apoptosis. Thus mammary tubulogenesis seems to involve ...
[43]
Epigenetic modifications in obesity‐associated diseases - Long - 2024
Feb 24, 2024 · Epigenetic modifications may influence both lipid metabolism and immune response. Epigenetic research showed significantly different epigenome ...
[44]
Clinical features, diagnosis, and evaluation of gynecomastia in adults
In true gynecomastia, a ridge of glandular tissue will be felt that is reasonably symmetrical to the nipple-areolar complex ...
[45]
https://emedicine.medscape.com/article/120858-workup
[46]
Breast cancer in men - PMC - NIH
Risk factors for male breast cancer include family history, gene mutations (BRCA2, BRCA1), age, Klinefelter syndrome, chest radiation and altered testosterone– ...
[47]
Gynecomastia Workup: Approach Considerations
Aug 1, 2024 · Breast imaging, through mammography or ultrasonography, may be controversial, because gynecomastia is much more common than male breast cancer.
[48]
Evaluation of the Symptomatic Male Breast - AC Search
Variant 1: Imaging is not recommended for the initial imaging of a male patient of any age with symptoms of gynecomastia and physical examination consistent ...<|control11|><|separator|>
[49]
Gynaecomastia and breast cancer in men - PMC - PubMed Central
Male carriers of BRCA2 have a cumulative risk for breast cancer of 7% by age 80. The excess risk in male carriers of BRCA1 is much less. Table 2 shows other ...
[50]
Core needle biopsy in male breast lesions - PMC - NIH
A core biopsy showed gynaecomastia, which was confirmed in the excision specimen. At that time, we had only limited experience with FNAC of the breast, male or ...
[51]
EAA clinical practice guidelines-gynecomastia evaluation ... - PubMed
May 16, 2019 · Assessment should comprise a thorough medical history and physical examination of the breast and genitalia (including testicular ultrasound).
[52]
Needle core biopsy for the assessment of unilateral breast masses ...
Core biopsy is a safe and effective method of diagnosing unilateral male breast swelling, which allows either confident reassurance or definitive treatment.
[53]
Gynecomastia: cytologic features and diagnostic pitfalls in fine ...
Apocrine metaplasia and epithelial atypia are common findings in gynecomastia. Attention to the cell patterns, the presence of sheets of ductal cells and ...
[54]
Morphological Features and Immunohistochemical Profiling of Male ...
Jun 23, 2022 · Microscopically, the early stage of gynaecomastia (florid phase) is characterised by proliferative branching ducts with epithelial and stromal ...
[55]
Aromatase and steroid receptors in gynecomastia and male breast ...
ER and PR expression was observed in the nuclei of ductal cells in all the cases of gynecomastia. More than 10% of the carcinoma cells were positive for ER ...
[56]
Ductal Carcinoma In situ of the Male Breast - PMC - PubMed Central
In males with gynecomastia, it is important to remember that ductal carcinoma in situ, even of high grade, is difficult to detect on mammography and may not be ...
[57]
Ductal Carcinoma In situ of the Male Breast - PubMed
Aug 5, 2016 · Background: Ductal carcinoma in situ of the male breast is an unusual lesion and most often associated with invasive carcinoma.
[58]
Surgical Treatment of Gynecomastia by Vacuum-Assisted Biopsy ...
Postoperative complications included 1 case of hematoma, but no nipple necrosis, local skin necrosis, or skin buttonhole occurred. No other operation-related ...
[59]
evolutionary progression from gynecomastia to aggressive male ...
Jun 18, 2024 · Gynecomastia denotes the benign proliferation of glandular breast tissue and stands as a recognized risk factor for male breast cancer.
[60]
Tamoxifen to treat male pubertal gynaecomastia - PMC - NIH
As 90% of pubertal gynaecomastia will resolve within three years, surgery should be reserved for persistent cases, large and pendulous breasts unresponsive to ...Missing: rate | Show results with:rate
[61]
Gynecomastia What the Surgeon Needs to Know - PMC - NIH
Pubertal gynecomastia has a peak prevalence of nearly 65% and occurs at about 14 years of age., Older men also develop involutional gynecomastia, with a ...
[62]
Drug-induced gynecomastia in children and adolescents - PMC
Adolescents who use anabolic steroids, or who abuse alcohol, marijuana, heroin, or amphetamines, should be alerted to the fact that gynecomastia might develop.Missing: avoidance | Show results with:avoidance
[63]
Compression Vests Assist Patients Before and After Body ...
Sep 15, 2009 · Compression Vests Assist Patients Before and After Body Contouring Surgery ... Gynecomastia treatment includes surgical and non-surgical options.
[64]
Management of gynecomastia - UpToDate
Sep 27, 2024 · SUMMARY AND RECOMMENDATIONS · INTRODUCTION · GENERAL PRINCIPLES · INITIAL MANAGEMENT · Stop offending drugs · Treat underlying condition ...
[65]
Gynecomastia Treatment & Management - Medscape Reference
Aug 1, 2024 · Generally, no treatment is required for physiologic gynecomastia. Pubertal gynecomastia resolves spontaneously within several weeks to 3 years in approximately ...
[66]
A retrospective cohort study of tamoxifen versus surgical treatment ...
Mar 13, 2023 · In one cohort study, TAM was shown to achieve complete remission in 90% of gynecomastia patients [11]. Another study recommended the use of TAM ...
[67]
Role of tamoxifen in idiopathic gynecomastia: A 10-year prospective ...
Our results show approximately nine in every 10 men treated with tamoxifen therapy had successful resolution of their symptoms.
[68]
Gynecomastia: A systematic review of pharmacological treatments
Nov 1, 2022 · The reported prevalence of pubertal gynecomastia (PG) is up to 70% (2). The typical onset of true PG occurs at 13–14 years of age, or at Tanner ...Missing: neonates | Show results with:neonates
[69]
Gynecomastia: A systematic review of pharmacological treatments
Oct 31, 2022 · Size reduction in patients treated with anastrozole occurred in 36.1%–72.2% (27–29) of patients, with a good response observed after one month ...Abstract · Introduction · Results · Discussion
[70]
Safety and efficacy of anastrozole for the treatment of ... - PubMed
Anastrozole treatment was well tolerated. In patients with pubertal gynecomastia, no significant difference in the percentage of patients with a 50% or greater ...
[71]
Comparison of tamoxifen with danazol in the ... - PubMed
Complete resolution of the gynecomastia was recorded in 18 patients (78.2%) treated with tamoxifen, whereas only 8 patients (40%) in the danazol group had ...
[72]
Endocrine Hormones and Their Impact on Pubertal Gynecomastia
Cytokines, growth factors, or hormones secreted by tumor cells can trigger paraneoplastic syndromes as a result of systemic effects, where the secreted ...Missing: apoptosis | Show results with:apoptosis
[73]
Management of adolescent gynecomastia: an update - PMC - NIH
In thirty eight patients with persistent pubertal gynecomastia who received reassurance alone or a 3- to 9-month course of an estrogen receptor modifier ...Introduction · Etiologies And Pathogenesis · Pharmacological Treatment
[74]
Long-Term Follow-up of Recurrence and Patient Satisfaction After ...
Mar 9, 2017 · Long-term follow-up results showed that recurrence rates are significantly higher in patients with lipomatous gynecomastia than in patients with glandular ...
[75]
Gynaecomastia | Breast Cancer Now
Having gynaecomastia does not increase your risk of developing breast cancer, but it's still important to be breast aware. Go back to your GP if you notice any ...
[76]
Gynecomastia in Adolescents: Impact on Mental Health and Body ...
Jun 18, 2025 · This study aimed to explore depression, anxiety, and body image issues in adolescents with gynecomastia.
[77]
The psychological burden of idiopathic adolescent gynecomastia
Compared with the general population, measures of anxiety, depression, and social phobia were significantly elevated in patients with gynecomastia; 100 percent ...Missing: impact | Show results with:impact
[78]
The Relationship between Psychopathology, Self-esteem, Body ...
In our study, we found that gynecomastia, depending on its stage, may lead to internalization disorder and impair self-esteem and body perception.Missing: distress | Show results with:distress
[79]
What Are the Psychological Impacts of Gynecomastia? - iCliniq
Mar 18, 2024 · In the group under study, depression and even suicidal thoughts were prevalent, primarily in patients with pendulous gynecomastia. Here is a ...
[80]
Psychological effects of social appearance anxiety and peer bullying
Apr 24, 2025 · Conclusions: Adolescents with gynecomastia had higher levels of anxiety, depression, and social appearance anxiety. They are more likely to be ...Missing: impact | Show results with:impact
[81]
Effects of Gynecomastia Surgery on Readiness and Return to Duty ...
Jul 3, 2024 · Gynecomastia surgery is associated with a detriment to personnel readiness. Surgery should be reserved for patients with severe symptoms ...Missing: relationships career fitness
[82]
Evaluation of Glandular Liposculpture as a Single ... - PubMed
Results: The patient mean (SD) overall satisfaction score was 4.7 (0.7), in which 92% of the responders were "satisfied" to "very satisfied". The mean (SD) BEQ ...Missing: percentage | Show results with:percentage
[83]
Gynecomastia in adolescent males: current understanding of its ...
Apr 30, 2024 · It is the source of significant embarrassment and psychological stress in adolescent males. GM is characterized by enlargement of the male ...
[84]
How Influencers Are Raising Awareness About Gynecomastia
These campaigns are crucial in reducing the shame and misinformation surrounding gynecomastia. Men are increasingly realizing that the condition is not a ...Missing: 30-50% | Show results with:30-50%
[85]
Top Celebrities With Gynecomastia | Man boobs | Dr Raja Mohan
Jul 13, 2024 · 1. Dwayne “The Rock” Johnson · 2. John Travolta Plastic Surgery · 3. Simon Cowell · 4. Arnold Schwarzenegger · 5. Jack Nicholson · 6. Jack Black.Missing: portrayals | Show results with:portrayals
[86]
Tutankhamun and His Brothers: Familial Gynecomastia in the ...
Jul 11, 1980 · The feminine physique and other abnormalities of Amenophis IV have been extensively commented on as indicative of some sort of pathological ...
[87]
Plastic Surgery for Gynecomastia - Medscape Reference
Jun 6, 2023 · Galen introduced the term gynecomastia in the second century AD. He defined gynecomastia as an unnatural increase in the breast fat of males.
[88]
History of Gynecomastia | Miguel Delgado M.D.
Rating 4.8 (652) The term "gynecomastia" was introduced in the 2nd century AD. Galen first described it, and Paulus of Aegina first attempted surgical treatment. Webster's 1946 ...Missing: Egyptian papyri 20th milestones
[89]
Gynecomastia. The origins of mammary swelling in the male
He injected a very large mammary gland from a 73-year-old man at postmortem and published the findings on the structure of the ducts. In 1861, John. Hunter3I ...
[90]
[PDF] Gynecomastia — a difficult diagnostic problem - Via Medica Journals
The term gynecomastia (Greek: gyne = woman, ma- stos = breast) was introduced in the first century A.D. by Galen. Gynecomastia is marked by a benign, abnor-.
[91]
[PDF] Wilson's disease - King's Research Portal
The first possible case of Wilson's disease was described by Frerichs (1861) in a 9-year-old boy with ... Cirrhosis: (35%–60%) Patients may present ...
[92]
Gynecomastia: A Clinical Review
Mastectomy for gynecomastia through a semicircular intra- areolar incision. Ann Surg 1946;125:557. 29. Illouz YG. The origin of lipolysis. In: Hetter GP, ed ...
[93]
Gynecomastia induced in normal males by spironolactone - 1978
Eighteen individuals received spironolactone (10 in the low-dose group and 8 in the high-dose group); of these, 8 developed gynecomastia. There were none in the ...
[94]
https://www.wikidoc.org/index.php/Gynecomastia_historical_perspective
[95]
What Accounts for the Increased Incidence of Gynecomastia ...
The authors speculate that the increasing incidence over time could be due to changes in the sex steroid hormone environment, possibly due to environmental ...
[96]
A comparative study on the short-term and long-term efficacy of ...
Feb 21, 2025 · This study investigates the comparative short-term and long-term efficacy of endoscopic lipolysis and liposuction versus traditional open excision in the ...
[97]
Gynecomastia historical perspective - wikidoc
Nov 9, 2017 · Gynecomastia was known since Aristotle, named by Galen, with surgical treatment by Paulus and Al-Zahrawi. Şerefeddin Sabuncuoğlu later ...
[98]
Gynecomastia - Etymology, Origin & Meaning
Gynaecomastia, from Greek gyneco- "woman" + mazos "breast" + -ia, means the condition of a man having breasts like a woman's.Missing: Galen | Show results with:Galen
[99]
The social context for psychological distress from ... - PubMed
Abstract. Introduction: Gynecomastia (breast development in males) is a side effect of androgen deprivation therapy (ADT) for prostate cancer (PCa).Missing: malignancy | Show results with:malignancy
[100]
[PDF] GYNECOMASTIA, HEGEMONIC MASCULINITY, AND STIGMA
Because gynecomastia is a condition whereby males exhibit bodies incongruent with standards of masculinity, breasted-men may be subject to stigmatization ...
[101]
Gynecomastia: The Impact of COVID-19 Pandemic on its Awareness
We believe, restrictions due to COVID-19 has had a positive impact in creating awareness among patients suffering from gynecomastia.
[102]
Celebrities With Gynecomastia: In Hollywood, Bollywood, and ...
Dec 27, 2024 · Well-known celebrities like Dwayne "The Rock" Johnson and Jack Black have openly discussed their experiences with gynecomastia.Missing: disclosures destigmatization
[103]
Cultural gynaecomastia - PubMed
Cultural gynaecomastia. ... MeSH terms. Communication Barriers; Culture*; England; Gynecomastia / etiology*; Humans; India / ethnology ...Missing: perceptions | Show results with:perceptions
[104]
https://www.databridgemarketresearch.com/reports/global-gynecomastia-procedures-market
[105]
A Review of the Current Insurance Coverage Criteria - PubMed
This study reviews US insurance policies for coverage of gynecomastia surgery and compares these policies to the guidelines put forth by the American Society ...